Close menu

December 15th, 2021 | 11:35 CET

Valneva, XPhyto Therapeutics, Pfizer - Corona is far from defeated

  • Biotechnology
Photo credits:

In an interview, new Health Minister Karl Lauterbach said, "We will not succeed in defeating Corona completely in the foreseeable period." By period, he probably means his term, which is four years. Thus, the hope that arose in the middle of the year related to a quick end by vaccination seems to have been dashed. The new Omicron variant cannot yet be fully assessed. It is causing uncertainty on the stock markets, which puts renewed pressure on companies that have already suffered from Corona. On the other hand, there are also the profiteers who are fighting Corona. Today we analyze three of these potential profiteers.

time to read: 4 minutes | Author: Armin Schulz
ISIN: VALNEVA SE EO -_15 | FR0004056851 , XPHYTO THERAPEUTICS | CA98421R1055 , PFIZER INC. DL-_05 | US7170811035

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Valneva - Poor study results weigh on shares

    Vaccine manufacturers are the biggest winners from the Corona pandemic. Valneva is betting on a so-called dead vaccine against the virus. This conventional vaccination method could make it easier to convince vaccination skeptics to vaccinate. The approach with dead vaccines has been practiced for decades and usually causes only minor side effects. The EU already secured 60 million doses of the VLA2001 vaccine in November, although it is still in phase 3 clinical trials.

    On December 2, there was a setback when a Southampton study was published that evaluated seven different vaccines for safety and efficacy as boosters. There were no limitations on safety; however, for efficacy, the vaccine did not meet predefined criteria for a minimal clinically meaningful difference in people vaccinated with two doses of Pfizer-BioNTech. It remains to be seen whether the EU will approve the vaccine.

    The Company responded immediately and issued a press release. It pointed out that the participants had received the booster vaccination relatively early, and thus the results had been negatively affected. The Company itself will set up a heterologous study and administer the booster vaccine only after 6 months. Nevertheless, the news came too late for the stock. It fell by more than 20% after the study announcement. At its peak, the share price fell from EUR 27.80 to EUR 19.60. A comprehensive analysis of the Company can also be found at

    XPhyto Therapeutics - Acquires 3a-diagnostics

    Since rapid tests are free of charge again in Germany, demand increases significantly. Here, XPhyto Therapeutics comes into play. Together with 3a-diagnostics GmbH, XPhyto Therapeutics has developed a PCR test that delivers results within about 25 minutes after sample collection. Thus, this test has a clear time advantage over conventional PCR tests, which require 4 to 6 hours in the laboratory alone to obtain a result. Therefore, it is ideal for all areas of application that require rapid results, such as airports or hospitals that need a quick diagnosis for accident victims.

    On November 29, the Company closed a private placement of 7 million Canadian dollars (CAD). CAD 4.5 million was raised through the issuance of shares at CAD 1 each. CAD 2.5 million was raised through a convertible debenture, which is convertible into shares at CAD 1.25 and bears interest at 8%. The money was used to finance the acquisition of 3a-diagnostics, which was announced on December 6. Peter Damouni expressed his satisfaction with the strategic acquisition, saying, "The integration of a highly innovative European biosensor development company puts XPhyto at the forefront of the point-of-care rapid testing industry, an explosively developing and technology-driven sector." 3a-diagnostics additionally has a pipeline of biosensor screening tests for a wide variety of viral diseases.

    In addition to diagnostics, two other business units exist at XPhyto. First, the Company develops innovative drug delivery systems. Secondly, the Company is involved in psychedelic agents that could combat mental illness. More detailed information about the different business areas can be found in the analysis on Currently, the focus is on the diagnostics area, where demand is now highest. The share has been in a downward trend since mid-February and is presently quoted at CAD 1.10. In February, the price was still at CAD 3.45. As soon as the Company can report larger orders for PCR tests, opportunities will arise.

    Pfizer - Acquisition of Arena Pharmaceuticals

    For Pfizer, the collaboration with BioNTech has more than paid off. The German Company was the first to present an effective vaccine called Comirnaty against the Coronavirus. For Pfizer, the active ingredient is an absolute goldmine. More than 50% of sales are attributable to the vaccine. Now that more booster vaccinations are needed, and the first children between the ages of 5 and 11 are being vaccinated, it can be assumed that this trend will continue for the time being. Not only have sales climbed significantly but so have profits.

    The profits were invested in the acquisition of Arena Pharmaceuticals on December 13. The deal cost the Group USD 6.7 billion. It paid a premium of over 100% to Friday's closing price. Arena's expertise in inflammation and immunology ideally complements Pfizer's portfolio. The drug Etrasimod, a potential blockbuster, is in a phase 3 trial, which is very promising. The sales potential is estimated at over USD 1 billion in a fast-growing market.

    Despite the business doing well, the stock has not performed nearly as well as BioNTech. Since the low in the first Corona wave in March 2020 of USD 26.43, the share has more than doubled and is currently trading at USD 55.20. In the coming quarter, the Company will pay a dividend of USD 0.40. Calculated over the year, the dividend is about 2.9%. The takeover may give rise to new fantasies, but one should wait for a setback before entering the market.

    All three companies can profit enormously from the Corona Crisis if the tests are successful and marketed accordingly. Valneva is waiting for EU approval and can then start shipping. XPhyto Therapeutics has three mainstays. At the moment, the rapid PCR tests are most marketable. The share should pick up as soon as a larger order comes in. Pfizer is a well-known pharmaceutical company that will make its way even without Corona. Nevertheless, profits are rising here as well during Corona.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.


    Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST

    Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments

    • Sustainability
    • Pharma
    • Biotechnology
    • renewableenergies
    • CarbonCredits

    Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.


    Commented by André Will-Laudien on July 11th, 2024 | 06:45 CEST

    Mega rally on the cards - 500% plus is likely too low an estimate! Evotec, Desert Gold, Cogia, VCI Global, and Lufthansa

    • Mining
    • Gold
    • Commodities
    • Biotechnology
    • airline

    The stock market keeps rising and rising - this much is revealed by the ever-new highs of prominent indices such as the NASDAQ 100, S&P 500, or the Nikkei index. However, a closer look reveals some inconsistencies. For example, only 6% of all traded stocks are currently reaching new highs, while over 70% of all listed stocks have fallen since the beginning of the year. In short, global liquidity is aggregated in just a few blockbuster stocks, with the rest being left behind. Such bubbles already occurred in 1999, 2007, and 2015, followed by a 25% to 50% correction. When exactly this will happen, no one knows, but the party is likely to continue for a while due to high liquidity. Gold and silver are in the process of forming interesting breakout formations. Now is the time to pick the cherries!